跳到正文
原文
Medical Xpress·· 8 天前精选AI 评分75

神经元在运动神经元疾病模型中恢复通信

Human neurons regain communication in motor neuron disease lab models

AI 导读

一项新研究发现,通过纠正TDP-43基因错误,可以恢复运动神经元疾病模型中神经元的通信。研究团队设计了一种特定的反义寡核苷酸药物,能够恢复功能性的UNC13A蛋白生产,使神经元再次通信。该药物已进入临床试验阶段。

推荐理由

研究揭示了TDP-43基因错误如何导致神经元通信中断,并提出了一种潜在的治疗策略。

正文
neuron
Credit: Public Domain

A novel potential treatment approach for motor neuron disease (MND), similar to the approach being pursued with an investigational drug that recently entered human clinical trials, has been shown to restore broken communication between neurons in lab models of the disease. This could have beneficial therapeutic implications for 97% of people with MND, for whom there is currently no significant disease-modifying treatment.

In a new study published in Nature, researchers from King's College London, University College London (UCL) and the Francis Crick Institute, along with Leibniz-FMP and Trace Neuroscience, pinpointed a single error in a key gene involved in MND that causes communication between neurons to break down, and used a drug to restore it in human neurons in the lab.

MND/ALS is a devastating and ultimately fatal disease that causes progressive muscle weakness due to the degeneration of motor neurons in the brain and spinal cord. As the disease advances, patients gradually lose the ability to move, speak, swallow and breathe. It is estimated to affect 1 in 300 people in their lifetime, and there is no cure.

A proofreading failure disrupts neuron signals

Currently, there are approved and experimental treatments for two rare genetic forms of ALS, which account for under 3% of cases. There is no significant disease-modifying treatment available for the remaining 97%. All of these cases share one feature: a key protein called TDP-43 stops doing its job correctly.

Normally, this protein is a proofreader for genetic material. Without this proofreading protein, neurons cannot process genetic material correctly, resulting in faulty proteins that are unable to carry out their normal roles.

By recreating in the lab what happens in human neurons when TDP-43 fails, researchers were able to see the knock-on effects of losing this proofreading protein on how neurons function. They found that without proper proofreading, there were errors in the production of another key protein called UNC13A that normally lets neurons send signals to each other. Common genetic variants in UNC13A are already among the strongest known risk factors for MND.

Correcting UNC13A restores communication

The study found that a single error in how UNC13A is produced drastically reduced neuron communication. The researchers designed a type of drug, called an antisense oligonucleotide (ASO), to specifically target this error and were able to restore production of functional UNC13A protein, letting the neurons communicate again.

Another ASO that targets UNC13A dysfunction through a similar mechanism is already in clinical development in humans in the U.K., Europe and China. Last month, the first U.K. participants were dosed with TRCN-1023 in Trace Neuroscience's Phase I/II FUNCTION ALS clinical trial. UCL is a participating trial site.

A single target amid widespread disruption

Regarding the new Nature findings, Professor Juan Burrone, professor of developmental neurophysiology at the Institute of Psychiatry, Psychology & Neuroscience at King's College London, said, "We were surprised to see that restoring just one genetic event, out of the hundreds disrupted, was enough to allow neurons to talk to each other again.

"It has been a truly collaborative effort across multiple institutes to work out what actually happens to neurons when TDP-43 fails. That we were able to restore signaling between neurons from rescuing a single genetic error gives us a promising molecular target for treatment of this devastating disease."

Pietro Fratta, professor of cellular and molecular neuroscience at UCL and group leader at the Francis Crick Institute, said, "Our previous work told us UNC13A is important in ALS progression, but we still did not know in which way and to what extent it plays a role. We have now learned it's the main driver of synaptic release deficits upon TDP-43 dysfunction, and have developed very effective antisense oligonucleotides to rescue this deficit. Excitingly, these drugs have already entered clinical trials."

Publication details

Keuss et al., UNC13A splice correction rescues synaptic dysfunction induced by TDP-43 loss, Nature (2026). DOI: 10.1038/s41586-026-11256-2

Journal information: Nature

Key medical concepts

Motor Neuron Disease

Clinical categories

Neurology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Human neurons regain communication in motor neuron disease lab models (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-human-neurons-regain-communication-motor.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com